Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. April 2024 04:53 ET | Quelle: Research and Markets

Biomaterials Market Analysis 2024-2029 by Type, Application and Region - Rising Opportunities in Personalized, Smart, Nanoengineered, and Sustainable Biomaterials

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Global Biomaterials Market by Type (Metallic (Gold, Magnesium), Ceramic (Aluminum Oxide, Carbon), Polymer (Polyethylene, Polyester), Natural...
29. April 2024 09:00 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
29. April 2024 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the...
29. April 2024 06:45 ET | Quelle: Ocugen

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
29. April 2024 06:00 ET | Quelle: Coave Therapeutics

Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route

coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...
26. April 2024 09:05 ET | Quelle: Ocugen

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
26. April 2024 07:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter...
26. April 2024 06:30 ET | Quelle: Ocugen

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
25. April 2024 16:05 ET | Quelle: Adverum Biotechnologies, Inc.

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
25. April 2024 09:00 ET | Quelle: Opthea Limited

Opthea to Present at the OIS Retina Innovation Summit at ARVO

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...

Vorherige Seite

Nächste Seite